Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis

Schizophrenia Research

Volumn 182, Issue , 2017, Pages 42-48

  Wils, Regitze Sølling ^b   Gotfredsen, Ditte Resendal ^b   Hjorthøj, Carsten ^b,c   Austin, Stephen F ^a,b   Albert, Nikolai ^b   Secher, Rikke Gry ^b   Thorup, Anne Amalie Elgaard ^b   Mors, Ole ^a,c   Nordentoft, Merete ^b,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c Lundbeck Foundation Initiative for Integrative Psychiatric Research IPSYCH   (Denmark)

Author keywords

Antipsychotic medication; First episode psychosis; Long term outcome; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG USE; FEMALE; FOLLOW UP; GENDER; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OCCUPATION; OUTCOME ASSESSMENT; PSYCHOSIS; REMISSION; SCHIZOPHRENIA; SUBSTANCE ABUSE; ADOLESCENT; LONGITUDINAL STUDY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85006013279     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.10.030     Document Type: Article

References (29)

1. Andreasen, N., et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162:3 (2005), 441–449.
2. Austin, S.F., et al. Predictors of recovery in first episode psychosis: the OPUS cohort at 10 year follow-up. Schizophr. Res. 150 (2013), 163–168.
3. Bertelsen, M., et al. Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch. Gen. Psychiatry 65:7 (2008), 762–771.
4. Cassidy, C.M., et al. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr. Bull. 36:5 (2010), 1001–1008.
5. Emsley, R., et al. The nature of relapse in schizophrenia. BMC Psychiatry, 13(1), 2013, 50.
6. Endicott, J., Spitzer, R.L., Fleiss, J.L., Cohen, J., The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 33:6 (1976), 766–771.
7. Gaebel, W., et al. Relapse prevention in first-episode schizophrenia—maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German research network on schizophrenia. J. Clin. Psychiatry 72:2 (2011), 205–218.
8. Gitlin, M., et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am. J. Psychiatry 158:11 (2001), 1835–1842.
9. Häfner, H., et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr. Res. 6:3 (1992), 209–223.
10. Harrison, G., et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Brit. J. Psychiat. 178 (2001), 506–517.
11. Harrow, M., Jobe, T.H., How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up. Schizophr. Bull. 36:1 (2010), 192–204.
12. Harrow, M., Jobe, T.H., Faull, R.N., Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol. Med. 42:10 (2012), 2145–2155.
13. Hasan, A., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J. Biol. Psychiatry 14:1 (2013), 2–44.
14. Hjorthøj, C.R., Vesterager, L., Nordentoft, M., Test-retest reliability of the Danish Adult Reading Test in patients with comorbid psychosis and cannabis-use disorder. Nord. J. Psychiatry 67:3 (2013), 159–163.
15. Køster, A., et al. Gender differences in first episode psychosis. Soc. Psychiatry Psychiatr. Epidemiol. 43:12 (2008), 940–946.
16. Leucht, S., Abraham, D., Kissling, W., Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35 (1999), 51–68.
17. Leucht, S., et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:9831 (2012), 2063–2071.
18. Marshall, M., et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch. Gen. Psychiatry 62:9 (2005), 975–983.
19. Mitchell, A.J., et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr. Bull. 39:2 (2013), 306–318.
20. Morgan, C., et al. Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychol. Med. 44:13 (2014), 1–14.
21. Petersen, L., et al. A randomised multicentre trial of integrated versus standard treatment for patient with a first episode of psychotic illness. BMJ, 10(11), 2005, 7.
22. Riecher-Rössler, A., Häfner, H., Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr. Scand. Suppl. 102:407 (2000), 58–62.
23. Robinson, D.G., et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 161:3 (2004), 473–479.
24. Takeuchi, H., et al. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr. Res. 134:2–3 (2012), 219–225.
25. Thorup, A., et al. Gender differences in first-episode psychosis at 5-year follow-up - two different courses of disease? Results from the OPUS study at 5-year follow-up. Eur. Psychiatry, 2013.
26. Wing, J., et al. SCAN. Schedules for clinical assessment in neuropsychiatry. Arch. Gen. Psychiatry, 47(January), 1990, 2190539.
27. Wunderink, L., et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J. Clin. Psychiatry 68:5 (2007), 654–661.
28. Wunderink, L., et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiat. (Chicago, Ill.) 70:9 (2013), 913–920.
29. Zipursky, R., Menezes, N., Streiner, D., Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr. Res., 2013, 1–7.